Insulin degradation and the mechanisms controlling it have significant impact on glucose homeostasis and diabetes. Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that the results from a recent collaborative research project with Pfizer will be presented at the 2012 Keystone Symposia: “Pathogenesis of Diabetes: Emerging...
Integration Creates Seamless Data Management and Analysis Capability for ARA Customers Advanced Research Associates, Inc. (ARA) and Rosa & Co. LLC jointly announced today an alliance that will provide Rosa’s noncompartmental pharmacokinetic analysis (NCA) capability to ARA customers as part of ARA’s seamless data management and biostatistics offering. “ARA’s partnership with Rosa allows us to...
Alliance combines innovative exploratory study design, leading in silico drug development capabilities, and a global licensing network to increase the value of emerging company portfolios and address pipeline gaps for established drug manufacturers. Rosa & Co. LLC (www.rosaandco.com) today announced that it has formed a strategic scientific alliance with FOCUS-IP (www.focus-ip.de), a leading...
Rosa & Co. LLC today announced that Dr. Jogarao V. Gobburu, Head of the US FDA Division of Pharmacometrics, will present the inaugural webinar in Rosa’s monthly public webinar series “Impact of Modeling & Simulation in Drug Development” ” on April 18, 2011 at 1:00 pm EDT (GMT -5:00). The purpose of the “Impact” series is to foster the use of Modeling and Simulation (M&S) activities in...